Literature DB >> 17628602

Severe spinal cord ischemia subsequent to fibrocartilaginous embolism.

Jan Thöne1, Andreas Hohaus, Andreas Bickel, Frank Erbguth.   

Abstract

Fibrocartilaginous embolism is a rare cause of spinal cord ischemia. Here we report the case of a young previously healthy man who noted sudden thoracic spinal belt-like pain after intensive physical effort. Following a free interval he developed paraplegia, complete sensory loss below Th(4) and inability to voluntarily purge bladder and bowel. Neuroimaging exposed an intramedullary longitudinal hyperintense signal from C(6) down to the conus in T2-weighted images, intersomatic disc collapses and vertebral body infarctions (C(5-7)/Th(8-10)). Other plausible diagnosis, e.g. spinal contusion, cord compression or acute onset transverse myelitis were excluded. Altogether, clinical presentation, neuroimaging and lack of evidence of other plausible diagnosis suggest fibrocartilaginous embolism as the most probable diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17628602     DOI: 10.1016/j.jns.2007.06.009

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Characterization of blood flow in the mouse dorsal spinal venous system before and after dorsal spinal vein occlusion.

Authors:  Matthew J Farrar; Jonathan D Rubin; Darcy M Diago; Chris B Schaffer
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

2.  Fibrocartilaginous embolic myelopathy: demographics, clinical presentation, and functional outcomes.

Authors:  Brittany J Moore; Anna M Batterson; Marianne T Luetmer; Ronald K Reeves
Journal:  Spinal Cord       Date:  2018-05-25       Impact factor: 2.772

3.  Acute Partial Brown-Séquard Syndrome Secondary to Intraforaminal Disc Prolapse and Spinal Cord Infarction.

Authors:  Athanasios Astreinidis; Stephanos Finitsis; Xanthippi Mavropoulou; Elisavet Psoma; Panagiotis Prassopoulos
Journal:  Case Rep Neurol Med       Date:  2019-09-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.